(Telestock) – GVSa company listed on Euronext Milan and active in the supply of filtering solutions for applications in the Healthcare & Life Sciences, Energy & Mobility and Health & Safety sectors, has closed the first semester 2024 with consolidated revenues equal to 214.8 million euros, up 1.6% on an annual basis at constant exchange rates and 0.7% at current exchange rates.
L’Normalized EBITDA is equal to 52 million euros, up 10.6% compared to the first six months of 2023, with a margin on revenues equal to 24.2%, significantly improving compared to the margin recorded in the first half of 2023, equal to 22.1%. normalized net result stood at 22.5 million euros, up 12.3%.
L’adjusted net financial debt as of June 30, 2024, it is equal to 241.6 million euros. The reduction compared to December 31, 2023, equal to a total of 10.6 million, is mainly due to the cash generated by operating activities (54.4 million), net of the liquidity absorbed by the changes in working capital (1.7 million) and used for net investments in tangible and intangible fixed assets for the period (a total of 19.2 million), for net financial expenses (9.4 million), for the payment of taxes (7.2 million) and for the subscription/renewal of leasing contracts (4.9 million).
The company confirms, with regard to turnover and the adjusted leverage ratio, the forecasts communicated at the time of approval of the 2023 financial year results, while revises upwards annual EBITDA margin forecast normalized, and therefore expects to achieve the following results in fiscal 2024: low-to-mid single digit growth in consolidated revenue compared to fiscal 2023; a normalized EBITDA margin growing between 150 and 250 basis points compared to fiscal 2023, up from the previous forecast of between 100 and 200 basis points; an adjusted leverage ratio expected at December 31, 2024 in the region of 2x.
(Photo: © Veerasak Piyawatanakul)